Another Mass Retraction

Springer is pulling 64 papers from 10 of its journals because of “fabricated peer-review reports.”

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PIXABAY, PUBLICDOMAINPICTURESFollowing up on the hunch of an editor who noticed irregularities in the reviewers suggested by submitting authors, Springer has identified more than five dozen papers that were published through manipulated peer review. The publisher is now pulling 64 papers, which were published in 10 of its journals, it announced today (August 17).

“The peer-review process is one of the cornerstones of quality, integrity, and reproducibility in research, and we take our responsibilities as its guardians seriously,” the publisher’s statement reads. “We are now reviewing our editorial processes across Springer to guard against this kind of manipulation of the peer review process in future.”

Specifically, “we are working to support our external editors to make them aware of the issues and ensure that thorough checks of peer reviewers are completed,” Springer’s William Curtis, executive vice president for medicine and biomedicine, elaborated in an email to The Scientist. “Credentials from peer reviewers will be increasingly checked by our editorial office, which support our editors-in-chief, and some journals may request more information in the form of an institutional email address ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo